{"id":64248,"date":"2026-04-29T21:47:41","date_gmt":"2026-04-29T13:47:41","guid":{"rendered":"https:\/\/flcube.com\/?p=64248"},"modified":"2026-04-29T21:47:42","modified_gmt":"2026-04-29T13:47:42","slug":"changchun-high-new-techs-gensci161-bispecific-antibody-receives-nmpa-approval-for-non-infectious-uveitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64248","title":{"rendered":"Changchun High &amp; New Tech&#8217;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial"},"content":{"rendered":"\n<p><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced that its <strong>GenSci161<\/strong> has received <strong>clinical trial approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for evaluation as a treatment for <strong>non-infectious uveitis (NIU)<\/strong>, expanding the drug&#8217;s development program across multiple inflammatory indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-summary\">Regulatory Milestone Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GenSci161 (novel fully human IgG1 bispecific antibody)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Non-infectious uveitis (NIU)<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>Endometriosis and moderate-to-severe hidradenitis suppurativa<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Multiple Phase II-ready indications<\/td><\/tr><tr><td><strong>Platform Technology<\/strong><\/td><td>OmniMab ultra-long-acting multispecific antibody platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-mechanism-of-action\">Technology Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bispecific-antibody-design\">Bispecific Antibody Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Class:<\/strong> Novel fully human IgG1 bispecific antibody (BsAb)<\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Simultaneously inhibits <strong>IL-1\u03b1<\/strong> and <strong>IL-1\u03b2<\/strong> subtypes of interleukin-1<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks activation of downstream inflammatory signaling pathways<\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> Potently neutralizes IL-1\u03b1\/\u03b2 without binding to endogenous IL-1RA, preserving natural regulatory mechanisms<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ultra-long-acting-platform\">Ultra-Long-Acting Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc Engineering:<\/strong> Leverages Changchun High &amp; New Tech&#8217;s proprietary <strong>OmniMab platform<\/strong><\/li>\n\n\n\n<li><strong>Half-Life Extension:<\/strong> Significantly prolonged pharmacokinetic profile<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Subcutaneous administration at <strong>8\u201312 week intervals<\/strong><\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Enables long-term systemic treatment with reduced injection frequency<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-strategy\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><th>Therapeutic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Non-infectious Uveitis (NIU)<\/strong><\/td><td>NMPA approval granted<\/td><td>IL-1 pathway central to ocular inflammation<\/td><\/tr><tr><td><strong>Endometriosis<\/strong><\/td><td>Clinical studies cleared<\/td><td>Chronic inflammatory condition driven by IL-1<\/td><\/tr><tr><td><strong>Hidradenitis Suppurativa<\/strong><\/td><td>Clinical studies cleared<\/td><td>Autoinflammatory disease with IL-1 involvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The <strong>multi-indication strategy<\/strong> demonstrates GenSci161&#8217;s potential as a broad-spectrum anti-inflammatory therapeutic targeting the fundamental IL-1 pathway across diverse disease states.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-positioning\">Market Opportunity &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-infectious Uveitis Market:<\/strong> Affects approximately 120,000 patients in the U.S. alone; limited treatment options available<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> 8\u201312 week dosing interval represents significant improvement over current biologics requiring weekly or bi-weekly administration<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> Dual IL-1\u03b1\/\u03b2 inhibition with preserved regulatory mechanisms offers novel mechanism of action<\/li>\n\n\n\n<li><strong>Chinese Innovation:<\/strong> Represents advanced biologics development capability from Chinese pharmaceutical company<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Successful advancement of OmniMab platform demonstrates technical leadership in Fc engineering<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Multiple inflammatory indications reduce development risk and expand commercial opportunity<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Robust mechanism of action and convenient dosing support international development strategy<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Combination of bispecific design, selectivity, and ultra-long half-life creates substantial competitive moat<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, and competitive developments in the inflammatory disease space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a (1).\"><\/object><a id=\"wp-block-file--media-8ade791d-5c89-49fd-aa07-fb788d442c81\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci161\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8ade791d-5c89-49fd-aa07-fb788d442c81\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,1171],"class_list":["post-64248","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Tech&#039;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug&#039;s development program across multiple inflammatory indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Tech&#039;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug&#039;s development program across multiple inflammatory indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64248\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T13:47:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T13:47:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Tech&#8217;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial\",\"datePublished\":\"2026-04-29T13:47:41+00:00\",\"dateModified\":\"2026-04-29T13:47:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64248#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64248\",\"name\":\"Changchun High &amp; New Tech's GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-29T13:47:41+00:00\",\"dateModified\":\"2026-04-29T13:47:42+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China's National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug's development program across multiple inflammatory indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64248\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Tech&#8217;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Tech's GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China's National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug's development program across multiple inflammatory indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64248","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Tech's GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China's National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug's development program across multiple inflammatory indications.","og_url":"https:\/\/flcube.com\/?p=64248","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-29T13:47:41+00:00","article_modified_time":"2026-04-29T13:47:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64248#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64248"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Tech&#8217;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial","datePublished":"2026-04-29T13:47:41+00:00","dateModified":"2026-04-29T13:47:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64248"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64248#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64248","url":"https:\/\/flcube.com\/?p=64248","name":"Changchun High &amp; New Tech's GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-29T13:47:41+00:00","dateModified":"2026-04-29T13:47:42+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its GenSci161 has received clinical trial approval from China's National Medical Products Administration (NMPA) for evaluation as a treatment for non-infectious uveitis (NIU), expanding the drug's development program across multiple inflammatory indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64248"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Tech&#8217;s GenSci161 Bispecific Antibody Receives NMPA Approval for Non-Infectious Uveitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64248"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64248\/revisions"}],"predecessor-version":[{"id":64251,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64248\/revisions\/64251"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}